阿片类药物治疗市场 - 全球产业规模、份额、趋势、机会及预测（按类型、诊断程序、症状、最终用户、地区和竞争格局划分，2021-2031 年）

全球斜视治疗市场预计将从 2025 年的 4.2317 亿美元成长到 2031 年的 6.5747 亿美元，复合年增长率为 7.62%。

该板块主要关注驱虫药的分销，特别是用于治疗由肝吸虫（Opisthorchis viverrini）和猫肝吸虫（Opisthorchis felinus）引起的肝吸虫感染疾病的吡喹酮。市场成长主要受东南亚和东欧流行地区持续的疾病负担所驱动，这些地区的国家公共卫生计画需要不断采购治疗方法。此外，政府加大对大规模药物管理活动的投入以及加强监测也是推动产业发展的关键因素。世界卫生组织（WHO）肝吸虫病研究与控制合作中心发布的2024年数据显示，大湄公河全部区域肝吸虫感染的总体盛行率为21.11%，证实了这些高风险地区对有效治疗方法的巨大需求。

儘管有这些正面因素，市场扩张仍面临诸多障碍：在疾病高发生率的偏远农村地区，灵敏的诊断工具取得管道有限。依赖灵敏度通常较低的显微镜粪便检验会导致诊断延误，从而限制了可治疗的患者群体。此外，除吡喹酮外缺乏其他替代治疗方法，增加了抗药性的风险，进一步加剧了市场长期永续性。

市场驱动因素

在流行地区，肝吸虫感染率的不断上升是市场成长的主要驱动因素，尤其是在东南亚，这种寄生虫在农村人口中根深蒂固。不断上升的感染率导致对驱虫药物的持续需求，因为公共卫生机构正努力控制感染循环，而传统饮食习惯（包括食用生鱼）又加剧了感染循环。这种持续的流行状况需要持续依赖药物干预来降低发病率并避免严重的肝臟併发症。根据《贫穷传染病》杂誌2024年5月通报，寮国人民民主共和国肝吸虫感染的总盛行率为34.06%，显着高于区域平均水平，凸显了在这些高负担地区采取治疗措施的迫切性。

同时，各国政府为因应寄生虫病所采取的策略性倡议，正透过加强检测和根除工作，改变市场格局。世界各地的卫生部门都将根除肝吸虫作为优先事项，以预防胆管癌等继发性併发症，并扩大吡喹酮的采购和供应。例如，根据《老虎》杂誌2024年2月报道，泰国卫生署製定了一项雄心勃勃的目标，即透过对高风险族群进行全面筛检，到2025年将肝吸虫感染率降低到1%以下。这项政策的根本动力在于疾病带来的严重长期健康风险。根据美国国立卫生研究院2024年12月发表的研究，泰国东北部胆管癌的年龄调整发生率仍然极高，为每10万人年13.4例，这亟需采取积极的预防和治疗策略。

市场挑战

全球华支睾吸虫病治疗市场的成长受到偏远农村地区缺乏准确诊断工具的显着阻碍。在高流行地区，依赖灵敏度低的显微镜粪便检验常常漏诊轻症感染。这种诊断缺口导致假阴性率居高不下，造成大量感染者未确诊。因此，驱虫药的潜在市场被人为地限制，因为药品采购订单通常是基于确诊病例数，而非实际的流行病学负担。

无法准确识别患者直接阻碍了治疗机构的收入成长。当国家卫生计画由于监测数据不足而无法掌握感染的真实规模时，就无法证明增加吡喹酮采购预算的合理性。这种对疾病严重程度的系统性低估造成了疾病持续流行与市场表现之间的脱节。根据「联合抗击被忽视的热带疾病组织」（Uniting to Combat NTDs）预测，到2024年，全球约有16.2亿人需要接受被忽视的热带疾病（NTD）治疗，但由于病例发现不足等障碍，治疗覆盖率仍有显着缺口。这种差距凸显了诊断方面的局限性如何严重限制了该行业的商业性潜力。

市场趋势

将治疗纳入胆管癌预防计划的倡议，从根本上重塑了抗寄生虫疗法的策略部署，将寄生虫控制与癌症控制直接联繫起来。公共卫生通讯协定正日益将吡喹酮纳入更广泛的监测体系，例如胆管癌筛检和护理计划，以预防与长期感染相关的致癌进展。这一转变使市场地位从单纯的驱虫药提升为重要的肿瘤预防策略，并确保政府对治疗的持续投入。 2024年2月发表在《亚太癌症预防日誌》上的一项针对泰国东北部胆管癌的分析报告显示，在为期10年的筛检期内，该地区胆管癌的总体发生率为每10万人32例，这印证了此类综合干预模式的必要性。

同时，「同一健康」疾病控制模式的应用正将市场从人类治疗扩展到环境和宿主管理领域。这项综合策略利用先进的空间建模技术来识别涉及中间宿主的感染热点，并指导更精准的社区介入资源分配。透过针对寄生虫的生态週期，这些模型正在推动高风险地区对监测工具和标靶治疗宣传活动的需求。根据2024年11月发表于《兽医学前沿》（Frontiers in Veterinary Science）的一项关于水资源中肝吸虫感染空间预测的研究，优化的地理加权回归模型实现了R² 0.800的预测准确率，显示在识别和控制复杂水环境中的感染源方面取得了显着进步。

目录

第一章概述

第二章调查方法

第三章执行摘要

第四章：客户评价

第五章 全球肝吸虫病治疗市场展望

• 市场规模及预测
  • 按金额
• 市占率及预测
  • 按类型（药物治疗、手术）
  • 透过诊断程序（造影、MRI、超音波、 电脑断层扫描、其他）
  • 根据症状（黄疸、腹泻、发烧、脾肿大、体重减轻、心搏过速等）
  • 按最终使用者（医院/诊所、门诊护理中心、其他）
  • 按地区
  • 按公司（2025 年）
• 市场地图

6. 北美肝吸虫病治疗市场展望

• 市场规模及预测
• 市占率及预测
• 北美洲：国家分析
  • 我们
  • 加拿大
  • 墨西哥

7. 欧洲肝吸虫病治疗市场展望

• 市场规模及预测
• 市占率及预测
• 欧洲：国家分析
  • 德国
  • 法国
  • 英国
  • 义大利
  • 西班牙

8. 亚太地区阿片类药物治疗市场展望

• 市场规模及预测
• 市占率及预测
• 亚太地区：国家分析
  • 中国
  • 印度
  • 日本
  • 韩国
  • 澳洲

9. 中东和非洲肝吸虫病治疗市场展望

• 市场规模及预测
• 市占率及预测
• 中东和非洲：国家分析
  • 沙乌地阿拉伯
  • 阿拉伯聯合大公国
  • 南非

10. 南美洲肝吸虫病治疗市场展望

• 市场规模及预测
• 市占率及预测
• 南美洲：国家分析
  • 巴西
  • 哥伦比亚
  • 阿根廷

第十一章 市场动态

• 司机
• 任务

第十二章 市场趋势与发展

• 併购
• 产品发布
• 最新进展

第十三章 全球肝吸虫病治疗市场：SWOT分析

第十四章：波特五力分析

• 产业竞争
• 新进入者的可能性
• 供应商电力
• 顾客权力
• 替代品的威胁

第十五章 竞争格局

• Cipla Inc.
• Johnson & Johnson
• Sun Pharmaceutical Industries Ltd.
• Merck KGaA
• Boehringer Ingelheim International GmbH
• Pfizer Inc.
• GlaxoSmithKline plc
• F. Hoffmann-La Roche Ltd
• AbbVie Inc
• Mankind Pharma Limited

第十六章 策略建议

第十七章：关于研究公司及免责声明

The Global Opisthorchiasis Treatment Market is projected to expand from USD 423.17 Million in 2025 to USD 657.47 Million by 2031, reflecting a CAGR of 7.62%. This sector primarily focuses on the distribution of anthelmintic agents, particularly praziquantel, which are used to eliminate parasitic liver fluke infections caused by Opisthorchis viverrini and Opisthorchis felineus. The market's growth is largely sustained by the ongoing disease burden in endemic areas of Southeast Asia and Eastern Europe, which necessitates consistent procurement of therapeutic regimens by national public health programs. Furthermore, increased government investment in mass drug administration efforts and enhanced surveillance systems act as key catalysts for industry development. Data from the WHO Collaborating Centre for Research and Control of Opisthorchiasis in 2024 indicates a pooled prevalence of Opisthorchis viverrini infection of 21.11% across the Greater Mekong Subregion, underscoring the substantial demand for effective treatments in these high-risk territories.

Despite these positive drivers, market expansion faces a significant obstacle in the form of limited access to precise diagnostic tools in remote rural communities where the disease is most common. The dependence on microscopic stool examinations, which frequently exhibit low sensitivity, results in underdiagnosis and consequently limits the patient population identified for treatment. Additionally, the lack of alternative therapeutic options beyond praziquantel creates a vulnerability regarding potential drug resistance, further complicating the long-term sustainability of the market.

Market Driver

The increasing prevalence of opisthorchiasis in endemic regions serves as a major engine for market growth, especially within Southeast Asia where the parasite is deeply rooted in rural populations. Elevated infection rates fuel a continuous demand for anthelmintic medications as public health agencies attempt to manage transmission cycles promoted by traditional dietary practices involving raw fish consumption. This persistent endemicity guarantees a steady dependence on pharmacological interventions to reduce morbidity and avert severe hepatic complications. As reported by Infectious Diseases of Poverty in May 2024, the pooled prevalence of Opisthorchis viverrini infection in the Lao People's Democratic Republic was 34.06 percent, a figure notably above the regional average, highlighting the urgent need for therapeutic measures in these high-burden zones.

Concurrently, strategic government initiatives aimed at controlling parasitic diseases are transforming the market through intensified screening and eradication efforts. National health authorities are prioritizing the elimination of liver flukes to prevent downstream complications such as bile duct cancer, leading to increased procurement and distribution of praziquantel. For example, The Thaiger reported in February 2024 that the Thai Ministry of Public Health set a strict goal to reduce the liver fluke infection rate to below 1 percent of the population by 2025 via comprehensive screening of at-risk demographics. These policy mandates are bolstered by the serious long-term health risks linked to the condition; a study published by the National Institutes of Health in December 2024 noted that Northeastern Thailand maintains a critically high Age-Standardized Rate of cholangiocarcinoma at 13.4 per 100,000 person-years, requiring aggressive preventive treatment strategies.

Market Challenge

Growth in the Global Opisthorchiasis Treatment Market is significantly hampered by the scarcity of accurate diagnostic tools within remote rural communities. In these high-prevalence zones, the reliance on microscopic stool examination, known for its low sensitivity, often fails to identify lighter infections. This diagnostic shortfall leads to a high frequency of false negatives, leaving a large portion of the infected population undiagnosed. As a result, the addressable market for anthelmintic agents is artificially constrained, given that pharmaceutical procurement orders are typically based on confirmed case numbers rather than the actual epidemiological load.

The inability to accurately identify patients directly obstructs revenue growth for treatment providers. When national health programs are unable to verify the true scope of infection due to inadequate surveillance data, they cannot justify increased budgetary allocations for purchasing praziquantel. This systemic underestimation of disease volume generates a discrepancy between the persistent prevalence of the disease and market performance. According to Uniting to Combat NTDs, reports in 2024 indicated that while approximately 1.62 billion people globally needed interventions for neglected tropical diseases, a significant gap in treatment coverage remains due to barriers such as insufficient case detection. This disparity highlights how diagnostic limitations severely restrict the sector's realized commercial potential.

Market Trends

The integration of treatment into cholangiocarcinoma prevention programs is fundamentally reshaping the strategic deployment of anthelmintic therapies by connecting parasite eradication directly to cancer control measures. Public health protocols are increasingly incorporating praziquantel administration into broader screening structures, such as the Cholangiocarcinoma Screening and Care Program, to halt the carcinogenic progression associated with long-term infection. This transition elevates the market from simple deworming efforts to essential oncology prevention strategies, ensuring sustained government funding for therapeutic procurement. As highlighted in the Asian Pacific Journal of Cancer Prevention in February 2024, an article analyzing cholangiocarcinoma in Northeastern Thailand reported an overall incidence rate of 32 per 100,000 population over a decade-long screening period, reinforcing the necessity of these integrated intervention models.

Simultaneously, the adoption of One Health disease control models is broadening the market's scope beyond human therapeutics to include environmental and reservoir host management. This holistic strategy employs advanced spatial modeling to pinpoint transmission hotspots involving intermediate hosts, thereby directing more precise resource allocation for community-based interventions. By targeting the parasite's ecological cycle, these models stimulate demand for surveillance tools and focused treatment campaigns in high-risk areas. According to Frontiers in Veterinary Science in November 2024, a study on the spatial prediction of liver fluke infection in water resources demonstrated that an optimized geographically-weighted regression model achieved a prediction accuracy R-squared value of 0.800, significantly improving the capability to identify and manage infection sources in complex aquatic environments.

Key Market Players

• Cipla Inc.
• Johnson & Johnson
• Sun Pharmaceutical Industries Ltd.
• Merck KGaA
• Boehringer Ingelheim International GmbH
• Pfizer Inc.
• GlaxoSmithKline plc
• F. Hoffmann-La Roche Ltd
• AbbVie Inc
• Mankind Pharma Limited

Report Scope

In this report, the Global Opisthorchiasis Treatment Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Opisthorchiasis Treatment Market, By Type

• Medications
• Surgery

Opisthorchiasis Treatment Market, By Diagnostic Procedure

• Cholangiography
• MRI
• Ultrasonography
• CT scan
• Others

Opisthorchiasis Treatment Market, By Symptom

• Jaundice
• Diarrhea
• Fever
• Splenomegaly
• Weight loss
• Tachycardia
• Others

Opisthorchiasis Treatment Market, By End User

• Hospitals & Clinics
• Ambulatory Care Centers
• Others

Opisthorchiasis Treatment Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Opisthorchiasis Treatment Market.

Available Customizations:

Global Opisthorchiasis Treatment Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Opisthorchiasis Treatment Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Type (Medications, Surgery)
  • 5.2.2. By Diagnostic Procedure (Cholangiography, MRI, Ultrasonography, CT scan, Others)
  • 5.2.3. By Symptom (Jaundice, Diarrhea, Fever, Splenomegaly, Weight loss, Tachycardia, Others)
  • 5.2.4. By End User (Hospitals & Clinics, Ambulatory Care Centers, Others)
  • 5.2.5. By Region
  • 5.2.6. By Company (2025)
• 5.3. Market Map

6. North America Opisthorchiasis Treatment Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Type
  • 6.2.2. By Diagnostic Procedure
  • 6.2.3. By Symptom
  • 6.2.4. By End User
  • 6.2.5. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Opisthorchiasis Treatment Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Type
      • 6.3.1.2.2. By Diagnostic Procedure
      • 6.3.1.2.3. By Symptom
      • 6.3.1.2.4. By End User
  • 6.3.2. Canada Opisthorchiasis Treatment Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Type
      • 6.3.2.2.2. By Diagnostic Procedure
      • 6.3.2.2.3. By Symptom
      • 6.3.2.2.4. By End User
  • 6.3.3. Mexico Opisthorchiasis Treatment Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Type
      • 6.3.3.2.2. By Diagnostic Procedure
      • 6.3.3.2.3. By Symptom
      • 6.3.3.2.4. By End User

7. Europe Opisthorchiasis Treatment Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Type
  • 7.2.2. By Diagnostic Procedure
  • 7.2.3. By Symptom
  • 7.2.4. By End User
  • 7.2.5. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Opisthorchiasis Treatment Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Type
      • 7.3.1.2.2. By Diagnostic Procedure
      • 7.3.1.2.3. By Symptom
      • 7.3.1.2.4. By End User
  • 7.3.2. France Opisthorchiasis Treatment Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Type
      • 7.3.2.2.2. By Diagnostic Procedure
      • 7.3.2.2.3. By Symptom
      • 7.3.2.2.4. By End User
  • 7.3.3. United Kingdom Opisthorchiasis Treatment Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Type
      • 7.3.3.2.2. By Diagnostic Procedure
      • 7.3.3.2.3. By Symptom
      • 7.3.3.2.4. By End User
  • 7.3.4. Italy Opisthorchiasis Treatment Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Type
      • 7.3.4.2.2. By Diagnostic Procedure
      • 7.3.4.2.3. By Symptom
      • 7.3.4.2.4. By End User
  • 7.3.5. Spain Opisthorchiasis Treatment Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Type
      • 7.3.5.2.2. By Diagnostic Procedure
      • 7.3.5.2.3. By Symptom
      • 7.3.5.2.4. By End User

8. Asia Pacific Opisthorchiasis Treatment Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Type
  • 8.2.2. By Diagnostic Procedure
  • 8.2.3. By Symptom
  • 8.2.4. By End User
  • 8.2.5. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Opisthorchiasis Treatment Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Type
      • 8.3.1.2.2. By Diagnostic Procedure
      • 8.3.1.2.3. By Symptom
      • 8.3.1.2.4. By End User
  • 8.3.2. India Opisthorchiasis Treatment Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Type
      • 8.3.2.2.2. By Diagnostic Procedure
      • 8.3.2.2.3. By Symptom
      • 8.3.2.2.4. By End User
  • 8.3.3. Japan Opisthorchiasis Treatment Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Type
      • 8.3.3.2.2. By Diagnostic Procedure
      • 8.3.3.2.3. By Symptom
      • 8.3.3.2.4. By End User
  • 8.3.4. South Korea Opisthorchiasis Treatment Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Type
      • 8.3.4.2.2. By Diagnostic Procedure
      • 8.3.4.2.3. By Symptom
      • 8.3.4.2.4. By End User
  • 8.3.5. Australia Opisthorchiasis Treatment Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Type
      • 8.3.5.2.2. By Diagnostic Procedure
      • 8.3.5.2.3. By Symptom
      • 8.3.5.2.4. By End User

9. Middle East & Africa Opisthorchiasis Treatment Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Type
  • 9.2.2. By Diagnostic Procedure
  • 9.2.3. By Symptom
  • 9.2.4. By End User
  • 9.2.5. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Opisthorchiasis Treatment Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Type
      • 9.3.1.2.2. By Diagnostic Procedure
      • 9.3.1.2.3. By Symptom
      • 9.3.1.2.4. By End User
  • 9.3.2. UAE Opisthorchiasis Treatment Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Type
      • 9.3.2.2.2. By Diagnostic Procedure
      • 9.3.2.2.3. By Symptom
      • 9.3.2.2.4. By End User
  • 9.3.3. South Africa Opisthorchiasis Treatment Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Type
      • 9.3.3.2.2. By Diagnostic Procedure
      • 9.3.3.2.3. By Symptom
      • 9.3.3.2.4. By End User

10. South America Opisthorchiasis Treatment Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Type
  • 10.2.2. By Diagnostic Procedure
  • 10.2.3. By Symptom
  • 10.2.4. By End User
  • 10.2.5. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Opisthorchiasis Treatment Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Type
      • 10.3.1.2.2. By Diagnostic Procedure
      • 10.3.1.2.3. By Symptom
      • 10.3.1.2.4. By End User
  • 10.3.2. Colombia Opisthorchiasis Treatment Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Type
      • 10.3.2.2.2. By Diagnostic Procedure
      • 10.3.2.2.3. By Symptom
      • 10.3.2.2.4. By End User
  • 10.3.3. Argentina Opisthorchiasis Treatment Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Type
      • 10.3.3.2.2. By Diagnostic Procedure
      • 10.3.3.2.3. By Symptom
      • 10.3.3.2.4. By End User

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Opisthorchiasis Treatment Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Cipla Inc.
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. Johnson & Johnson
• 15.3. Sun Pharmaceutical Industries Ltd.
• 15.4. Merck KGaA
• 15.5. Boehringer Ingelheim International GmbH
• 15.6. Pfizer Inc.
• 15.7. GlaxoSmithKline plc
• 15.8. F. Hoffmann-La Roche Ltd
• 15.9. AbbVie Inc
• 15.10. Mankind Pharma Limited

16. Strategic Recommendations

17. About Us & Disclaimer